Clinical Trials
28 trialsNCT06833073 2026-05-28
INTerpath-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05951179 2026-05-18
ADVANCED-2
Protara Therapeutics
Phase 2 Recruiting
NCT04752722 2026-04-30
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
enGene, Inc.
Phase 1/2 Recruiting
NCT07283835 2026-04-23
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Lepu Biopharma Co., Ltd.
Phase 2 Recruiting
NCT07480356 2026-03-18
ADVANCED-3
Protara Therapeutics
Phase 3 Not yet recruiting
NCT04452591 2026-03-16
BOND-003
CG Oncology, Inc.
Phase 3 Active not recruiting
NCT06022029 2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1 Recruiting
NCT05014139 2025-11-20
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Astellas Pharma Inc
Phase 1 Terminated
NCT04368247 2025-08-07
Skin Fluorescent Imaging (SFI) System in Patients With Nevi
Orlucent, Inc
Completed
NCT07092007 2025-07-29
NWRD09 for HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer
Newish Technology (Beijing) Co., Ltd.
Phase NA Recruiting
NCT05085977 2025-01-27
ADVANCED-1
Protara Therapeutics
Phase 1 Completed
NCT05085990 2025-01-27
ADVANCED-1
Protara Therapeutics
Phase 1 Completed
NCT06741150 2024-12-18
NWRD09 for HPV-16 Positive and HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer Patients.
Newish Technology (Beijing) Co., Ltd.
Phase NA Recruiting
NCT04387461 2024-09-25
CORE-001
CG Oncology, Inc.
Phase 2 Completed
NCT01625260 2024-07-19
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Altor BioScience
Phase 1/2 Terminated
NCT02486640 2023-07-24
BETAPREDICT
Bayer
Completed
NCT04312737 2023-01-06
EU-VALHUDES
Hiantis Srl
Completed
NCT01438112 2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3 Terminated
NCT04109092 2020-12-14
A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
Eisai Inc.
Phase 1 Withdrawn
NCT03134573 2019-03-26
PROmyBETAapp
Bayer
Completed
NCT02471495 2018-05-07
RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)
Medical Enterprises Europe B.V.
Phase 3 Withdrawn
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01200992 2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3 Terminated
NCT00406068 2016-07-28
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
Bioniche Life Sciences Inc.
Phase 2/3 Completed
NCT01316874 2015-06-12
Bladder Cancer
Endo Pharmaceuticals
Phase 2/3 Completed
NCT01731652 2015-02-10
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Telormedix SA
Phase 2 Completed
NCT00141531 2012-06-14
Phase II Trial of EOquin in High-risk Superficial Bladder Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT00109655 2008-10-03
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
Cell Genesys
Phase 1 Unknown